Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV Lipodystrophy
| Autor: | Susana D'Amico, Mario Maldonado, Archana Rao, Ashok Balasubramanyam |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty chemistry.chemical_compound Fenofibrate Internal medicine Immunopathology Hyperlipidemia medicine Humans Hypertriglyceridemia Triglyceride Cholesterol business.industry HIV-Associated Lipodystrophy Syndrome General Medicine Middle Aged medicine.disease Endocrinology chemistry Female lipids (amino acids peptides and proteins) Lipodystrophy business medicine.drug Lipoprotein |
| Zdroj: | The American Journal of the Medical Sciences. 327:315-318 |
| ISSN: | 0002-9629 |
| DOI: | 10.1097/00000441-200406000-00003 |
| Popis: | Objective To determine the effectiveness of fenofibrate in treating hypertriglyceridemia associated with highly active antiretroviral therapy–associated HIV lipodystrophy syndrome (HLS). Methods The authors recruited from their HIV metabolic clinic 55 adult patients with anthropomorphic changes consistent with HLS together with hypertriglyceridemia. The patients had no prior history of taking lipid-lowering medications and were free of liver and renal disease. They were on various highly active antiretroviral therapy regimens, and these regimens were not altered during the course of the study. Fenofibrate was started at 54 mg a day and the dose increased every 2 weeks to a maximum of 162 mg/day. Fasting lipid concentrations were measured at baseline and 6 months after the intervention. Results At baseline, the fasting plasma concentrations of total cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol were 259 ± 11, 886 ± 172, and 35.7 ± 2.3 (mean ± SEM) mg/dL, respectively. After 6 months of fenofibrate treatment, the fasting plasma concentrations were as follows: total cholesterol, 243 ± 13; triglycerides, 552 ± 104, and HDL cholesterol, 35.7 ± 1.8 mg/dL. The decrease in fasting plasma triglyceride concentration was statistically significant (P 0.05). Fenofibrate was well tolerated, and no subjects dropped out of the study. Conclusion Fenofibrate is an effective, well-tolerated treatment for hypertriglyceridemia associated with HLS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|